PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics Releases Richard E. Uihlein’s Open Letter to Stockholders
NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today released this open letter to stockholders written by its Board Chair Richard E. Uihlein .  The letter reads as follows: Dear
View HTML
Toggle Summary Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants
Richard E. Uihlein, Board Chair, expresses interest in investing $20.0 million in the Rights Offering NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today filed a Registration
View HTML
Toggle Summary Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update
Planning for Phase 3 clinical trial (NASH-RX) nearing completion for GR-MD-02, the first drug to show positive results in a clinical trial in patients with compensated NASH cirrhosis NORCROSS, Ga. , March 06, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.
View HTML
Toggle Summary Galectin Therapeutics to Present at Berenberg NASH Day in New York
NORCROSS, Ga. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at Berenberg NASH Day at the Berenberg Offices
View HTML
Toggle Summary Galectin Therapeutics’ Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure
Board Chairman Richard Uihlein extends existing $10 million unsecured line of credit for two additional years NORCROSS, Ga. , Jan. 15, 2019 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its
View HTML
Toggle Summary Galectin Therapeutics Announces Extension of $10 Million Line Credit
NORCROSS, Ga. , Dec. 20, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that its $10 million unsecured line of credit entered into on December 19, 2017 , has been extended by one year for both
View HTML
Toggle Summary Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit
NORCROSS, Ga. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold H. Shlevin , the Company’s President and CEO, will present at the 2nd Annual Anti-Fibrotic Drug
View HTML
Toggle Summary Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update
NORCROSS, Ga. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today reported financial results for its third fiscal quarter, which ended September 30, 2018 , and provided a business update.
View HTML
Toggle Summary Data Collected by Exalenz Bioscience in Galectin Therapeutics’ Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting
NORCROSS, Ga. , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that an abstract based on results obtained in Galectin Therapeutics’ NASH-CX Phase 2 Clinical Trial has been accepted for
View HTML
Toggle Summary Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference
NORCROSS, Ga. , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the upcoming ROTH Capital Battle of the NASH Thrones Investor Conference being held
View HTML